Oncology vs Biosimilar: Which Therapeutic Focus for Foreign Pharma in China?

Foreign pharmaceutical companies evaluating their product strategy in China face a fundamental choice between two of the most dynamic segments of the market: innovative oncology therapeutics and the rapidly expanding biosimilars sector. Both offer substantial growth opportunities, but they operate on fundamentally different business models, require different capabilities, and carry distinct risk-return profiles. Oncology represents the cutting edge of pharmaceutical innovation, with premium pricing and significant clinical differentiation, while biosimilars offer volume-driven revenue with lower R&D risk but intense price competition. This article provides a comprehensive comparison of the oncology and biosimilar therapeutic focus areas for foreign pharma in China, examining market dynamics, regulatory pathways, competitive landscapes, and strategic implications to help companies make informed portfolio allocation decisions.

The Oncology Opportunity in China

China’s oncology market is the second largest in the world, valued at approximately USD 45 billion in 2024 and projected to grow at a compound annual growth rate of 12 to 15 percent through 2030. This growth is driven by several powerful factors: an aging population with increasing cancer incidence, rising diagnostic rates due to improved screening programs, expanding access to innovative therapies through NRDL coverage, and the emergence of China as a global hub for oncology clinical development. Cancer is the leading cause of death in China, with approximately 4.8 million new cancer diagnoses annually, creating enormous unmet medical need across a wide range of tumor types.

The competitive landscape in China’s oncology market has evolved dramatically over the past decade. Domestic Chinese biotech companies have emerged as formidable competitors, particularly in the immuno-oncology space, where products such as sintilimab, tislelizumab, and penpulimab have achieved NRDL listing and captured significant market share. Foreign pharma companies face intense competition from these locally developed PD-1 inhibitors, which are priced 30 to 50 percent below their imported counterparts. However, foreign companies maintain advantages in areas requiring deeper scientific expertise, including antibody-drug conjugates, bispecific antibodies, cell therapies, and precision oncology targeting rare mutations.

The regulatory pathway for oncology drugs in China has been substantially streamlined through reforms at the NMPA and CDE. Breakthrough therapy designation, priority review, and conditional approval pathways have reduced development timelines significantly. Oncology drugs now receive marketing authorization in China an average of two to three years after US or EU approval, compared to five to seven years historically. The CDE has also accepted foreign clinical trial data for registration in certain circumstances, reducing the need for large-scale China-specific studies. These reforms have made China an increasingly attractive market for launching innovative oncology products globally.

The Biosimilar Opportunity in China

China’s biosimilar market is experiencing explosive growth, driven by patent expiries of major biologic products, government policies promoting affordable biologic therapies, and the maturation of domestic biosimilar manufacturing capabilities. The market was valued at approximately USD 12 billion in 2024 and is projected to reach USD 35 billion by 2030, representing a compound annual growth rate of 19 percent. Key biologic reference products facing patent expiry in China include adalimumab, bevacizumab, rituximab, trastuzumab, and etanercept, creating significant opportunities for biosimilar entrants.

The competitive dynamics of the biosimilar market differ fundamentally from innovative oncology. Biosimilar competition is primarily price-driven, with multiple manufacturers offering essentially interchangeable products. The first biosimilar to market typically captures 40 to 50 percent market share, but subsequent entrants face rapidly declining margins as price competition intensifies. In the Chinese market, domestic companies have been particularly aggressive in biosimilar pricing, offering products at 30 to 60 percent discounts to the reference biologic. Foreign pharma companies entering the biosimilar space must compete on manufacturing efficiency, supply chain reliability, and brand trust rather than clinical differentiation.

The regulatory pathway for biosimilars in China is well-established, with the NMPA issuing comprehensive guidance on biosimilar development that aligns with international standards from the WHO, EMA, and FDA. The approval pathway requires comparative analytical studies, non-clinical evaluation, and clinical pharmacokinetic and pharmacodynamic studies demonstrating similarity to the reference product. However, the clinical development pathway for biosimilars is substantially shorter and less risky than for innovative oncology drugs, with development timelines of four to six years and clinical success rates exceeding 80 percent. This lower risk profile makes biosimilars an attractive option for foreign pharma companies seeking more predictable returns.

Head-to-Head Comparison: Oncology vs Biosimilars

Capability Requirements and Organizational Fit

The capability requirements for success in oncology versus biosimilars differ substantially and have important implications for organizational design. Successful oncology-focused companies in China require deep scientific expertise in disease biology, biomarker development, and clinical trial design for complex, often biomarker-driven studies. They need robust relationships with academic medical centers and key opinion leaders in oncology, sophisticated market access teams capable of navigating NRDL negotiations for high-cost therapies, and commercial teams that can educate physicians on novel mechanisms of action and patient selection criteria.

Biosimilar-focused companies require a different capability set. Manufacturing excellence and cost efficiency are paramount, as biosimilar competition is primarily price-driven. Companies need expertise in analytical characterization, process development, and scale-up to demonstrate comparability to the reference product. Commercial success depends on supply chain reliability, hospital procurement relationships, and the ability to compete effectively in volume-based procurement programs. The biosimilar commercial model is closer to a generics business than an innovative pharma model, requiring lean, efficient operations rather than large, specialized scientific teams.

Organizational culture also differs between the two focus areas. Oncology organizations thrive on innovation, risk-taking, and scientific excellence, with cultures that celebrate breakthrough discoveries and tolerate the high failure rate inherent in novel drug development. Biosimilar organizations emphasize operational discipline, cost control, and execution reliability, with cultures focused on manufacturing efficiency and commercial execution. Foreign pharma companies attempting to pursue both strategies within a single China organization face cultural tensions and resource allocation conflicts that must be managed carefully.

Financial and Portfolio Considerations

The financial profiles of oncology and biosimilar investments differ markedly. Oncology products offer the potential for blockbuster revenue but carry substantial development risk. A successful innovative oncology drug can generate USD 500 million to USD 2 billion in annual China revenue, with peak sales typically reached five to eight years after launch. However, the cost of failure is high: a Phase III trial failure in a novel oncology program can result in a write-off of USD 500 million or more in development costs. The risk-adjusted NPV of oncology programs is highly sensitive to clinical trial success probabilities and time to market.

Biosimilar products offer more predictable but lower-margin returns. A successful biosimilar in China can generate USD 100 million to USD 500 million in annual revenue, depending on the reference product’s market size and the number of competing biosimilars. The risk-adjusted return on investment for biosimilars is often attractive because of the high probability of technical success and relatively predictable development timelines. However, the market is becoming increasingly crowded, with China now having the highest density of biosimilar competitors globally. Late entrants to popular reference products may struggle to achieve viable returns.

Strategic Recommendations for Foreign Pharma

Most successful foreign pharma companies in China pursue a balanced portfolio that includes both oncology and biosimilar assets. The optimal allocation depends on the company’s risk tolerance, existing capabilities, and strategic objectives. Companies with strong global oncology pipelines and deep scientific capabilities should prioritize innovative oncology, leveraging their global R&D investment across markets. Companies with strong manufacturing capabilities and experience in competitive markets may find biosimilars a natural fit. For mid-sized foreign pharma companies, a focused strategy in a single therapeutic area is often more successful than a diluted approach across both, as it allows concentration of scarce resources on building distinctive capabilities.

The evidence suggests that foreign pharma companies that have achieved the greatest success in China have adopted a dual-track strategy. They maintain a pipeline of innovative oncology products for premium-priced NRDL and private insurance channels, while simultaneously building a biosimilar portfolio to capture volume-driven revenue in the increasingly cost-conscious Chinese healthcare system. This approach diversifies risk across development stages and commercial models, while allowing the company to leverage its China commercial infrastructure across both product categories.

Conclusion

The choice between oncology and biosimilars as a therapeutic focus is not a question of which market is better, but which is better suited to a particular company’s capabilities, strategy, and risk appetite. Oncology offers the potential for category-defining innovation and premium returns, but requires substantial investment and carries significant development risk. Biosimilars offer more predictable returns and lower development risk, but face intense price competition and require manufacturing excellence. The most successful foreign pharmaceutical companies in China recognize that both segments will be essential components of the country’s healthcare future, and they structure their portfolios to capture value from both while maintaining strategic focus and operational excellence in their chosen areas of competitive advantage.